Showing 3061-3070 of 5256 results for "".
- EWG Releases 2012 Sunscreen Guide and Apphttps://practicaldermatology.com/news/20120608-ewg_releases_2012_sunscreen_guide_and_app/2459787/After rating 257 brands and more than 1,800 products, the Environmental Working Group (EWG) released its sixth annual Guide to Summer Sun. EWG recommends 1 in 4 of more than 800 beach and sport sunscreens, compared to 1 in 5 l
- Psoriasis Genetic Map Explored by International Psoriasis Councilhttps://practicaldermatology.com/news/20120607-psoriasis_genetic_map_explored_by_international_psoriasis_council/2459788/The International Psoriasis Council (IPC) is leading the effort to establish collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis. Their
- Dermatologists Can Spot Early Psoriatic Arthritishttps://practicaldermatology.com/news/20120521-dermatologists_can_spot_early_psoriatic_arthritis/2459795/Clinical dermatologists could help diagnose early psoriatic arthritis (EPsA) through the use of patient questioning and subsequent imaging studies in collaboration with rheumatologists and radiologists, data suggest. (
- Study: FDA Approves Drugs Faster than Europe, Canadahttps://practicaldermatology.com/news/20120517-study_fda_approves_drugs_faster_than_europe_canada/2459797/Drugs are approved faster in the US than in Europe and Canada, new research from Yale University School of Medicine shows. Authors of the study, published in The New England Journal of Medicine, reviewed decisions from 2001 to 2010 by the FDA and regulators in Canada and Europe, Health Canada and th
- FDA Extends Deadline for Sunscreen Label Compliancehttps://practicaldermatology.com/news/20120514-fda_extends_deadline_for_sunscreen_compliance/2459802/Sunscreen manufacturers have won a small victory from the Food and Drug Administration (FDA), which has extended the deadline for compliance with new labeling back to December 2013 for some companies. The industry pushed back on the agency, which ordered changes to sunscreens last summer with an ori
- Celotres Earns CE Mark Approval for Wound Healinghttps://practicaldermatology.com/news/20120504-celotres_earns_ce_mark_approval_for_wound_healing/2459808/European regulators have granted CE Mark approval for Celotres™ hydrogel scaffold from Halscion, Inc. The CE Mark approval was based on the results of a prospective, multi-center, randomized, same-patient controlled, European clinical trial evaluati
- Ouchless Needle Announces First Exclusive International Distribution Agreement with Device Technologieshttps://practicaldermatology.com/news/20120501-ouchless_needle_announces_first_exclusive_international_distribution_agreement_with_device_technologies/2459811/Ouchless Needle by the BellaNovus Development Company announced their first international exclusive distribution agreement with Device Technologies for Australia and New Zealand. Developed by aesthetic plastic surgery innovator Marc J. Sa
- Enrollments Complete for Two Phase 2 ALA-PDT AK Trialshttps://practicaldermatology.com/news/20120424-enrollments_complete_for_two_phase_2_ala-pdt_ak_trials/2459815/DUSA Pharmaceuticals (NASDAQ GM: DUSA) completed patient enrollment in its Phase 2 clinical trial studying the broad area application with 1-, 2-, and 3-hour drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- Slight Uptick for Biologics Predicted in EUhttps://practicaldermatology.com/news/20120419-slight_uptick_for_biologics_predicted_in_eu/2459820/In a recent TreatmentTrends© study with EU5 dermatologists, BioTrends Research Group, LLC finds that there has been a slight increase in the use of biologics in all of the EU5 countries except Italy, where usage has remained constant. Future prescribing habits will see moderate increases in prescrib